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The immune response to recombinant adenoviruses is the most significant impediment to their clinical use for immunization.
We test the hypothesis that specific virus-antibody combinations dictate the type of immune response generated against the ade-
novirus and its transgene cassette under certain physiological conditions while minimizing vector-induced toxicity. In vitro and
in vivo assays were used to characterize the transduction efficiency, the T and B cell responses to the encoded transgene, and the
toxicity of 1 1011 adenovirus particles mixed with different concentrations of neutralizing antibodies. Complexes formed at
concentrations of 500 to 0.05 times the 50% neutralizing dose (ND50) elicited strong virus- and transgene-specific T cell re-
sponses. The 0.05-ND50 formulation elicited measurable anti-transgene antibodies that were similar to those of virus alone (P
0.07). This preparation also elicited very strong transgene-specific memory T cell responses (28.6 5.2% proliferation versus
7.7 1.4% for virus alone). Preexisting immunity significantly reduced all responses elicited by these formulations. Although
lower concentrations (0.005 and 0.0005 ND50) of antibody did not improve cellular and humoral responses in naïve animals,
they did promote strong cellular (0.005 ND50) and humoral (0.0005 ND50) responses in mice with preexisting immunity. Some
virus-antibody complexes may improve the potency of adenovirus-based vaccines in naïve individuals, while others can sway the
immune response in those with preexisting immunity. Additional studies with these and other virus-antibody ratios may be use-
ful to predict andmodel the type of immune responses generated against a transgene in those with different levels of exposure to
adenovirus.
Despite a concerted effort to develop recombinant adenovi-ruses for clinical gene transfer, the immune response induced
by the virus continues to be the most significant limitation of this
otherwise potent vector (20, 59). After systemic administration,
virus rapidly binds to complement and clotting factors that pro-
mote cell adhesion and sequestration of virus bymacrophages and
dendritic and Kupffer cells (1, 3, 15, 49, 55). This and efficient
transduction of hepatocytes stimulate release of numerous cyto-
kines and chemokines into the circulation (15, 59). Immediate
effects include thrombocytopenia and elevated liver enzymes, of-
ten transient and self-limiting. Virus-induced pathology can then
progress further, manifesting significant tissue injury, multiorgan
failure, and death (41). The innate response is further strength-
ened through Toll-like receptor-dependent and -independent
mechanisms (2, 31, 60). As a result, major histocompatibility
complex (MHC) class I-restricted CD8 andMHC class II helper
CD4 T cells specific for targets expressing viral gene and trans-
gene products are produced (22, 57, 58). In the context of gene
transfer, these responses limit the duration of gene expression and
compromise the potency of subsequent doses of vector in immu-
nocompetent individuals. In contrast, the innate response to ad-
enoviruses can effectively boost the immune response against an
encoded antigen, making them attractive for immunization plat-
forms (27, 28, 56). However, this response still hampers the clin-
ical utility of the virus for this purpose.
Adenovirus serotype 5, used in 414 clinical trials to date (http:
//www.wiley.co.uk/genmed/clinical/), is ubiquitous in nature and
infects humans frequently, making preexisting immunity to the
virus prevalent in the general population. Although anti-
adenovirus 5 antibody levels are generally low in children, they
increase with age (52) and vary according to geographical loca-
tion, with the lowest levels found in the United States (30 to 60%
of the population positive), moderate levels in Europe and Asia
(40 to 80% positive), and highest levels in sub-Saharan Africa (80
to 100% positive) (38). With the primary concern being neutral-
ization of virus particles and failure to produce sufficient amounts
of antigen required for protective immunity, early efforts to ad-
dress the issue of preexisting immunity involved isolation and
development of rare human and nonhuman adenovirus serotypes
as carriers (17, 21, 43, 44). These vectors do evade neutralization
by anti-adenovirus 5 antibodies; however, they are difficult to pro-
duce and elicit moderate immune responses against the encoded
antigen. Genetic modification of hexon proteins, the primary site
of antibody binding (50), covalent attachment of biocompatible
polymers to the capsid to deter antibody binding, production of
adenovirus chimeras from several different serotypes, and direct
incorporation of antigen-specific epitopes into the virus capsid
have improved the potency of adenovirus-based vaccines in those
with preexisting immunity to some degree (6, 16, 23, 47, 51, 54).
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Although reduction of the potency of an adenovirus-based
vaccine in those with preexisting immunity to adenovirus 5 is a
legitimate concern, recent results from a phase IIb clinical trial
suggest that virus-antibody complexes can significantly influence
the type of immune response generated by the vaccine carrier in a
another way that may not be appropriate in some infectious dis-
ease models. In this trial, it was initially thought that adenovirus-
antibody complexes triggered expansion of adenovirus-specific
effector CD4 cells, increasing the targets available for HIV infec-
tion (4, 36). Although it is still not clear if this was the primary
cause of the outcome of that trial (32), this and the fact that de-
velopment of alternative adenoviral vectors has not adequately
addressed the issue of preexisting immunity highlight the fact that
this immunological state in the general population is poorly char-
acterized and not well understood.
In this report, we test the hypothesis that specific virus-
antibody ratios dictate the types of immune responses generated
against the virus and the transgene cassette under certain physio-
logical conditions and that this information can be used to im-
prove and predict the potency of adenovirus-based vaccines in
certain patient populations. Experiments outlined in this paper
were explicitly designed to identify specific virus-antibody com-
binations that promote potent immune responses to an encoded
antigen and reduce virus-induced toxicity. In vitro and in vivo
assays were used to assess the transduction efficiency, the T and B
cell responses to the encoded transgene, and the toxicity profile of
a single dose of a model recombinant virus premixed with neu-
tralizing antibodies at various concentrations prior to administra-
tion to naïve mice. The utility of these complexes in animals with
established preexisting immunity is also discussed.
MATERIALS AND METHODS
Virus production. Wild-type (VR-5; ATCC, Manassas, VA) and first-
generation adenovirus serotype 5 vectors containing eitherEscherichia coli
beta-galactosidase (AdlacZ) or enhanced green fluorescent protein
(AdEGFP) were amplified and purified according to established methods
(53). All experiments were performed with freshly purified virus.
Infectious titer assay. Samples were serially diluted in Dulbecco’s
modified Eagle’s medium (Cellgro DMEM; Mediatech, Herndon, VA)
supplemented with 2% fetal bovine serum (FBS) (Gibco Invitrogen,
Grand Island, NY). Medium was removed from 12-well plates (BD Fal-
con, Bedford, MA) seeded with 1.5 104 293 cells/well and replaced with
0.1 ml of the appropriate dilution of virus. After 2 h at 37°C, 1 ml of
DMEM containing 10% FBS was added to each well. Sixteen hours later,
medium was removed and cells were fixed with 0.5% glutaraldehyde.
Beta-galactosidase activity was determined after treatment with the sub-
strate 5-bromo-4-chloro-3-indolyl-beta-galactoside (Gold Biotechnol-
ogy, St. Louis, MO) for 16 h at 37°C in the dark. Staining medium was
removed and blue lac cells were tallied from a minimum of 20 micro-
scope fields (approximately 48,000 cells). The number of infectious virus
particles was calculated as described previously (13).
Plaque assay. Plaque assays were performed according to established
protocols (19). Aliquots of virus (250l), serially diluted in DMEM, sup-
plementedwith 2%FBS, were added to 293 cells for 2 h at 37°C. Cells were
then overlaid with minimum essential medium (Gibco Invitrogen) con-
taining agarose (0.8%, SeaPlaque; BioWhittaker Molecular Applications,
Walkersville, MD), FBS (2%), and MgCl2 (10 mM). PFU were calculated
as described previously (5).
Production ofVACs.Virus-antibody complexes (VACs)were formed
by mixing freshly purified virus (1 1012 virus particles/ml) with a spe-
cific amount of stock anti-adenovirus serotype 5 antibody and gentamicin
(20g/ml; Abraxis Pharmaceutical Products, Schaumburg, IL) in Protein
LoBind microcentrifuge tubes (Eppendorf, Westbury, NY). Tubes were
affixed to a rocking platform shaker (Ames aliquot mixer; Siemens Med-
ical Solutions, Elkhart, IN) and gently agitated for 1 h at 37°C. Prepara-
tions were then placed on ice and immediately given to C57BL/6 mice.
The timeline for dosing, sample collection, necropsy, and assessment of
the immune response generated by VACs is summarized in Fig. 1.
Characterization of neutralizing antibody stock andVACs. (i) Anti-
adenovirus IgG isotyping. The types of antibodies generated during
production of the neutralizing antibody stock were identified by
enzyme-linked immunosorbent assay (ELISA) as described previously
(12). Briefly, high-binding polystyrene microtiter plates (Immulon 2HB;
ThermoScientific, Rochester,NY)were coatedwith 100l of AdlacZ (5
109 virus particles/well) in phosphate-buffered saline (PBS) (pH 7.4)
overnight at 4°C, washed four times with PBS containing 0.05% Tween
20, and blocked in PBS containing 1% bovine serum albumin (BSA)
(ELISA grade; Sigma) for 2 h at room temperature. Serum dilutions used
to form VACs were added to the antigen-coated plates for 2 h at room
temperature. Plates were washed four times and incubated with horserad-
ish peroxidasean (HRP)-conjugated rabbit anti-mouse IgG, IgG1, IgG2a,
IgG2b, and IgM antibodies (1:2,000 dilution; Southern Biotechnology
Associates, Birmingham, AL) for 1 h at room temperature. Plates were
washed, p-nitrophenyl phosphate in diethanolamine buffer was added
(Sigma-Aldrich, St. Louis, MO), and optical densities (OD) were read at
450 nmon amicroplate reader (TecanUSA, Research Triangle Park, NC).
(ii) Western blotting. Adenovirus structural proteins obtained from
20 g adenovirus (5  108 virus particles) were resolved in each indi-
vidual lane of a 9% gel via sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene
difluoride (PVDF) microporous membranes using a Trans-blot Turbo
FIG 1 Timeline for administration of virus-antibody complexes (VACs),
sample collection, necropsy, and assessment of the immune response for naïve
mice (A) and those with preexisting immunity (PEI) (B). Mice were given a
single dose of 1 1011 virus particles mixed with different concentrations of
anti-adenovirus antibodies (naïve mice) or 28 days after establishment of pre-
existing immunity by tail vein injection in a volume of 100 l. Control mice
were given 100l of sterile PBS and gentamicin in the samemanner. Six hours
after treatment, blood was collected from the saphenous vein and serum pro-
cessed for assessment of cytokines, platelets, and serum transaminases. Blood
was also collected on days 3 and 7 for assessment of serum transaminases and
platelets. Mice from each group (n  4) were sacrificed on days 4 and 7, and
portions of liver and spleen were cryopreserved for sectioning and histochem-
ical detection of beta-galactosidase. Remaining tissue and other organs (heart,
kidney, lung, lymph nodes) were harvested and snap-frozen for assessment of
virus distribution by real-time PCR. Ten days after treatment, mice (n  5)
were sacrificed and splenocytes processed for assessment of T cell responses.
Tissue samples were also taken at this time point for assessment of virus dis-
tribution patterns. On day 28, blood was collected from the saphenous vein of
remaining animals for characterization of anti-beta-galactosidase and anti-
adenovirus antibodies. These animals (5 per group) were sacrificed on day 42
and splenocytes processed for assessment of immunological memory by CFSE
staining and flow cytometry. †, terminal bleed and necropsy of animals at the
denoted time point.
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transfer system (Bio-Rad, Hercules, CA). The membrane was then cut
into individual lanes, and each was incubated with a specific serum dilu-
tion used to form VACs overnight at 4°C. Membranes were then incu-
bated with an HRP-conjugated rabbit anti-mouse IgG secondary anti-
body (1:25,000 dilution) for 1 h at room temperature. Blots were
developedwith the SuperSignalWest Pico chemiluminescent substrate kit
(Thermo Scientific, Rockford, IL), and membranes were exposed to Bio-
MaxMLfilm (Kodak, Rochester, NY) for 30min. Films were scanned and
analyzed usingKodak 1D image analysis software (EastmanKodak, Roch-
ester, NY).
(iii) Dynamic light scattering. Particle size of VACs was assessed with
a DynaPro LSR laser light scattering detection system (Wyatt Technology
Corporation, Santa Barbara, CA) according to established protocols (8).
Animal studies. All procedures were approved by the Institutional
Animal Care and Use Committee of the University of Texas at Austin and
are in accordance with the guidelines established by the National Insti-
tutes of Health for the humane treatment of animals.
Production of neutralizing antibody stock. Serum used to form
VACs was generated by immunizing 80male C57BL/6 (H-2b)mice (6 to 8
weeks old; Jackson Laboratory, Bar Harbor, ME) with 100 g of density
gradient-purified wild-type adenovirus 5. Virus was prepared as an emul-
sion with TiterMax Gold according to the manufacturer’s instructions
(Sigma-Aldrich). One hundred microliters of the final emulsion was in-
jected subcutaneously. Two weeks later, mice were given a second dose
prepared in the same manner. Blood was collected 2 weeks later from a
representative cohort (n 40) via the saphenous vein and serum screened
for anti-adenovirus neutralizing antibodies (NAB). Animals were sacri-
ficed and terminally bled 21 days later. Serum was collected, pooled, heat
inactivated, and stored in LoBindmicrocentrifuge tubes at80°Cprior to
use. The final NAB titer of this stock preparation was a 3,926 reciprocal
dilution.
Establishment of preexisting immunity (PEI) to adenovirus. PEI
was established inmale C57BL/6 (H-2b) mice (6 to 8 weeks) with 1 1011
particles ofAdEGFP (total volume, 100l) by direct injection of 50l into
each gastrocnemius muscle on the hind limb (Fig. 1B). Twenty-one days
later, blood was collected and serum screened for anti-adenovirus NAB.
Average anti-adenovirus NAB levels prior to administration of VACs
across treatment groups was a 184.2 32.4 reciprocal dilution.Mice were
givenVACs 7 days later (28 days post-PEI) by tail vein injection.Necropsy
and sampling times are the same as for naïve mice (Fig. 1).
Chromium release assay. Splenocytes were harvested on day 10,
pooled according to treatment, and cultured for 5 days at a density of 6
106 cells/well in RPMI 1640 medium (Mediatech) with 10% FBS and 50
M 2-mercaptoethanol (Sigma) in the presence of AdlacZ at a multiplic-
ity of infection (MOI) of 10 PFU/cell in 24-well culture plates. Activation
and cytolytic activity was determined by a classical chromium release
assay in whichMC57 (H-2b) target cells (1 106), infected for 24 hwith
AdlacZ (MOI, 100), were labeled with 100 Ci of 51Cr sodium (Perkin
Elmer, Waltham, MA) for 1 h at 37°C. Cells were washed and plated in
96-well round-bottomed plates (BD Falcon) in DMEM containing 10%
FBS at a density of 5  103 cells/well. Effector cells were then added at
different effector:target ratios (100:1, 50:1, 25:1, 12:1, 6:1, and 3:1) and
maintained at 37°C for 6 h. At this time, 100l of culture supernatant was
removed from each well and counted in a gamma counter (Beckman
Coulter, Fullerton, CA). The percentage of specific 51Cr release was cal-
culated as [(cpm of sample – cpm of spontaneous release)/(cpm of max-
imal release – cpm of spontaneous release)]  100. Spontaneous release
was determined by assaying target cells in the absence of effectors. Maxi-
mum release was determined by addition of 10% sodium dodecyl sulfate
(SDS) to target cells in the absence of effectors. Data represent average
values obtained from four wells.
Intracellular cytokine staining. Splenocytes isolated from mice on
day 10 were pooled according to treatment and ground through sterile
strainers (70 m; BD Falcon) into 50-ml conical tubes containing Liebo-
vitz’s L15medium (Mediatech). Cells were pelleted by centrifugation, and
red blood cells were removed by resuspending the pellet in an equal vol-
ume of ACK lysis buffer (Quality Biological, Inc., Gaithersburg, MD).
After several washes, cells were adjusted to a density of 2  106/well in
complete DMEM containing 10% FBS, 50 M 2-mercaptoethanol, pen-
icillin (10,000 IU/ml), streptomycin (10,000 g/ml) (Gibco, Invitrogen),
1 mM L-glutamine (HyClone, Salt Lake City, UT), 50 U/ml mouse
interleukin-2 (IL-2) (R & D Systems, Minneapolis, MN), 1 mM sodium
pyruvate (Lonza, Walkersville, MD), 1 mM nonessential amino acids
(Lonza), and 1 g/ml brefeldin A (Sigma). Cells were cultured for 6 h at
37°C in round-bottom 96-well plates with a peptide (DAPIYTNV; 1 g/
well; New England Peptide, Gardner, MA) which contains the beta-
galactosidase MHC class I restricted epitope for mice of the H-2b haplo-
type (34). Cells were pelleted, resuspended in PBS containing rat
fluorescein isothiocyanate (FITC)-labeled anti-mouse CD8a antibody
(BD PharMingen, San Diego, CA), and placed at 4°C for 30 min. Cells
werewashed 3 times, resuspended inCytoperm (BDBiosciences, San Jose,
CA), and stored at 4°C for 30 min. Cells were then stained with rat phy-
coerythrin (PE)-labeled anti-mouse IFN- antibody (BD PharMingen)
for 30 min at 4°C. Positive cells were counted using a FACSCalibur flow
cytometer (BD Biosciences). Over 250,000 events were captured per
sample. Data were analyzed with FCS Express (DeNovo Software, Los
Angeles, CA).
Carboxy fluorescein diacetate succinimidyl ester (CFSE) staining.
Expansion of T cells in response to beta-galactosidase-specific T peptide
was analyzed using the Vybrant CFDA SE cell tracer kit (Molecular
Probes, Eugene, OR) according to the manufacturer’s protocol. Spleno-
cytes were harvested, and 2 106 cells from each animal were incubated
in triplicate for 15 min with 1.5M carboxyfluorescein diacetate, succin-
imidyl ester (CFDA SE), at 37°C for 15 min. Cells were washed twice and
resuspended in completeDMEMwith orwithout theDAPIYTNVpeptide
(1g/well) and cultured for 5 days at 37°C. Staining for cell surfacemark-
ers was performed for 30min at 4°C with a cocktail of antibodies (PerCP-
Cy5.5-labeled anti-CD8, PE-labeled anti-CD44, and APC-labeled anti-
CD62L; BD PharMingen) and analyzed as described.
Detection of transgene-specific IgG. Twenty-four hours prior to col-
lection of serum, 96-well plates (Evergreen Scientific, Los Angeles, CA)
were coated with beta-galactosidase (1 g/well; enzyme immunoassay
[EIA] grade; Roche Applied Science, Indianapolis, IN) in PBS at 4°C.
Plates were washed 4 times with PBS containing 0.05% Tween 20 and
blocked in PBS containing 1% BSA for 1 h. Serum from each animal was
serially diluted in 2-fold increments, and 100 l of each was added to the
plate in triplicate. After incubation at 4°C overnight, the plate was washed
and HRP-conjugated rabbit anti-mouse IgG antibody (1:1,000 dilution;
Sigma) added for 2 h at room temperature.Wells were washed and 100l
of o-phenylenediamine (0.4 mg/ml, Sigma) added to each well. After 15
min, optical densities were read at 450 nm on a microplate reader. Fifty
percent endpoint titers were calculated according to the method of Reed
and Muench (42).
Anti-adenovirus neutralizing antibody assay. Serum was heat inac-
tivated at 56°C for 30 min. Each sample was serially diluted in serum-free
DMEM in 2-fold increments starting from a 1:20 dilution as described
previously (12). Each dilution (100 l) was mixed with 1  106 PFU of
AdlacZ, incubated for 1 h at 37°C, and then added to HeLa cells (CCL-2;
ATCC) seeded in 96-well plates (2 104 cells/well). One hundredmicro-
liters of DMEM supplemented with 20% FBS was added to each well after
1 h. Beta-galactosidase expression was assessed 24 h later. Neutralizing
antibody titers were calculated as the dilution at which beta-galactosidase
expression is reduced by 50% using the Reed and Muench method (42).
Evaluationof virusdistribution, gene expression, and toxicity.Beta-
galactosidase expression was assessed in tissue samples by histochemical
staining as described previously (11). The number of virus genomes in
tissue was determined by real-time PCR of genomic DNA extracts as
described previously (7). Serum cytokines were assessed by ELISA (Invit-
rogen, BioSource International, Camarillo, CA). Serum alanine amino-
transferase (ALT) and aspartate aminotransferase (AST) levels were mea-
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sured as described previously (7). Platelet counts were performed at the
University of Texas M.D. Anderson Keeling Center for Comparative
Medicine and Research, Bastrop, TX.
Statistical analysis. Data were analyzed for statistical significance by
performing a one-way analysis of variance (ANOVA) between control
and experimental groups, followed by Bonferroni-Dunn post hoc tests
when appropriate. Analysis was performed with SigmaStat software (Sys-
tat Software, Inc., Chicago, IL).
RESULTS
In vitro characterization of virus-antibody complexes. In an
initial pilot study, freshly purified virus containing the beta-
galactosidase transgene at a concentration of 1.0 1011 virus par-
ticles/ml was mixed with mouse-generated anti-adenovirus anti-
body at concentrations 500, 5, and 0.05 times the 50%neutralizing
dose (ND50) of the stock solution. The antibody stockmostly con-
sisted of anti-adenovirus IgG antibodies, with Ig2b being the pri-
mary isotype (Fig. 2A). Although a marked amount of IgM anti-
bodies was also found in the 500-ND50 preparation, this isotype
could not be detected in the 5- and 0.05-ND50 formulations.
Western blotting revealed that the antibodies were capable of
binding major adenovirus capsid proteins (hexon, penton, fiber)
in preparations with concentrations at and above 5 ND50 (lane 1,
Fig. 2B). The 0.05-ND50 preparation bound hexon alone (lane 3,
Fig. 2B). Addition of antibody at the 500-ND50 level reduced the
infectious titer of the virus by a factor of 4,000 (Table 1). The
infectious titer of the 5-ND50 preparation was somewhat lower
than that of the 500-ND50 preparation (1.60 0.55 108 versus
1.02 0.52 108 infectious virus particles/ml) while the titer of
the 0.05-ND50 preparation was approximately twice that amount
(2.30 0.55 108).
In vivo performance of virus-antibody complexes. Trans-
gene expression. Systemic administration of recombinant adeno-
viruses containing beta-galactosidase elicit measurable levels of
transgene expression in the marginal zones of the spleen (Fig. 3A)
and the liver (Fig. 3B) as early as 6 h after administration. Trans-
gene expression in the liver intensifies by day 4 (Fig. 3C) and peaks
by day 7 (Fig. 3D). Transgene expression could not be detected in
the spleens (Fig. 3E) or the livers of animals given the 500-ND50
preparation at any of the selected time points (Fig. 3F to H). Sim-
ilar results were obtained for the 5-ND50 preparation (data not
shown). Spotty transgene expressionwas detected in the spleens of
mice given the 0.05-ND50 preparation (Fig. 3I). Although notable
transgene expression could not be detected in the livers of these
animals at 6 h (Fig. 3J), some expression could be detected at 4
days (Fig. 3K), which intensified by day 7 (Fig. 3L) but was still
significantly less than that observed in mice given virus alone
(Fig. 3D).
Immune response. The T cell response was first evaluated by
51Cr release assays using splenocytes of mice given either the na-
tive virus or VACs. After incubationwithH-2b target cells infected
with native virus expressing beta-galactosidase, substantial cytol-
ysis was detected in samples from animals given unmodified virus
(AdlacZ; Fig. 4A). Formation of virus-antibody complexes did not
blunt the CTL response, as significant cytolysis was detected in
samples from all groups given these preparations. Negligible cy-
tolysis was observed with naïve, restimulated splenocytes (PBS).
In an effort to evaluate the ability of virus-antibody complexes
to strengthen the B cell-mediated immune response against anti-
gens encoded in adenovirus-based vaccines, serum was collected
and screened for anti-beta-galactosidase antibodies on day 28.
FIG 2 Characterization of stock serum by ELISA isotyping (A) and Western blotting (B). (A) Isotyping assays revealed that the antibody stock used to create
antibody-virus complexes mostly consisted of anti-adenovirus IgG antibodies with Ig2b being the primary isotype in the 500-, 5-, and 0.05-ND50 preparations.
Marked amounts of IgM antibodies were detected in the 500-ND50 preparation only. Values for isotypes present in the 0.005- and 0.0005-ND50 preparations fell
below the detection limit of the assay. Error bars indicate the standard deviations from the average results of 4 separate preparations for each serumconcentration.
(B)Western blot of adenovirus capsid proteins resolved on a 9%SDS-PAGE gel. Each lanewas incubatedwith a different dilution of stock serum. Lane 1, 5ND50;
lane 2, 0.5 ND50; lane 3, 0.05 ND50; lane 4, 0.005 ND50; lane 5, 0.0005 ND50. Serum concentrations at or above 5 ND50 bound the primary adenovirus capsid
proteins (hexon, penton, fiber). Fiber binding was lost at the 0.5-ND50 concentration. Hexon binding was detected in the 0.05- and 0.005-ND50 preparations.
Binding of adenovirus capsid proteins could not be detected at the 0.0005-ND50 concentration.
TABLE 1 Infectious titer as determined by two in vitro assays for each
production lot of virus-antibody complexesa
Treatment ITA (ivp/ml) PLA (PFU/ml)
PFU:IVP
ratio
Adenovirus alone 4.08 0.22 1010 4.5 0.48 1010 1:1.1
Virus 500 ND50 1.02 0.52 108 3.2 0.95 106 1:32
Virus 5 ND50 1.60 0.55 108 3.6 0.28 106 1:44
Virus 0.05 ND50 2.30 0.92 108 4.2 0.73 106 1:55
Virus 0.005 ND50 2.53 0.22 1010 NA
Virus 0.0005 ND50 3.62 0.15 1010 NA
a The input for each of these preparations was 1.0 1011 virus particles/ml, as
determined by measuring the absorbance of each preparation at 260 nm. ITA,
infectious titer assay; ivp, infectious virus particles; PLA, plaque assay; NA, not assayed.
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The most significant amount of antibody was found in animals
given virus alone (9,606 624 50% endpoint titer; Fig. 4B). Titers
were somewhat lower in animals receiving the 0.05-ND50 prepa-
ration (1,580 775 50% endpoint titer). Trace amounts of anti-
beta-galactosidase antibodies were detected in samples frommice
given the 500- and 5-ND50 preparations. Small amounts of anti-
adenovirus NABs were also detected in these groups (18.2  5.5
and 13.7  6.12 50% endpoint titers, respectively; Fig. 4C). The
amount of anti-adenovirus NABs present in animals given the
0.05-ND50 preparation were significantly lower than that of ani-
mals given the virus alone (108.5 6.36 versus 205.0 51.3 50%
endpoint titer, P 0.05).
CD8 T cell memory is a crucial component of protective
immunity against various pathogens. In this context, beta-
galactosidase-specific T cells were evaluated for their ability to
rapidly proliferate when pulsed with immunostimulatory pep-
tides from the cognate antigen. Five days after restimulation, an
average of 28.6 5.2% of effectormemory CD8T cells obtained
from mice given the 0.05-ND50 preparation had undergone pro-
liferation in response to the antigenic epitope (Fig. 4D). This was
significantly higher than that of mice given virus alone (7.7 
1.4%, P 0.01) and the other virus-antibody preparations (1.2
0.5% and 1.5 0.5%, 500 and 5 ND50, respectively).
Toxicity profiles of virus-antibody complexes. The immune
response against capsid proteins is largely responsible for the tox-
icity associated with systemic administration of recombinant ad-
enoviral vectors (46). Thus, several biochemical markers were
measured over time to delineate the toxicity profiles of virus-
antibody complexes.
Proinflammatory cytokines. Serum was collected 6 h after
treatment and analyzed for IL-6 and IL-12, markers commonly
associated with activation of the innate immune response against
recombinant adenoviruses (2). This time point was selected be-
cause cytokine concentrations peak approximately 6 h after virus
infection and rapidly decline within 24 h (20). Samples from ani-
mals given virus alone contained the highest concentrations of
both cytokines (223.4 7.6 pg/ml IL-6, 246.3 26.8 pg/ml IL-12;
Fig. 5A). The 500-ND50 preparation reduced IL-6 by a factor of 2,
while samples from mice given the 0.05-ND50 preparation con-
tained the lowest levels of this cytokine (6.5  2.8 pg/ml, P 
0.01). IL-12 was also significantly lower in this treatment group
with respect to mice given virus alone (86.1  16.9 pg/ml, P 
0.05). A similar trend was also noted for the 500- and 5-ND50
preparations (106.02 22.8 pg/ml and 144.2 37.8, respectively;
P 0.05).
Platelets.Baseline platelet counts formice used in these studies
was 1,105.1 41.6 103/l (Fig. 5B). Three days after treatment,
a significant drop to 762.5  86.3  103/l was detected in ani-
mals given virus alone (P  0.001). This returned to baseline 4
days later. Platelet counts from mice given the 5- and 0.05-ND50
preparations (1,110.0 83.5 and 1,105.1 41.6 103/l, respec-
tively) were not statistically different than those from animals
given saline (PBS, 1,007.5  74.5  103/l, P  0.07) and re-
mained unchanged throughout the study. Similar results were ob-
tained for animals given the 500-ND50 preparation.
Serum transaminases. Serumalanine aminotransferase (ALT)
and aspartate aminotransferase (AST) levels were used tomonitor
hepatotoxicity associated with systemic administration of adeno-
virus (Fig. 5C and D). Animals given virus alone experienced sig-
nificant elevations in serum AST at days 4, 7, and 10 after treat-
ment with respect to saline controls (2, 29, and 20 times baseline,
respectively; P 0.001) (Fig. 5D). AST levels of mice given any of
FIG 3 VACs elicit limited transgene expression after systemic administration. First-generation adenoviral vectors were mixed with various concentrations of
mouse anti-adenovirus antibodies and given to C57BL/6mice by tail vein injection (1 1011 particles/ml). Animals were sacrificed and livers were evaluated for
beta-galactosidase expression by histochemical staining 6 h (second column), 4 days (third column), and 7 days (fourth column) after administration. Samples
obtained from the spleen were also evaluated for transgene expression at the 6-h time point (first column). Transgene expression could not be detected in any
samples from mice given the 500-ND50 preparation (E to H). Similar results were found for the 5-ND50 preparation (data not shown). Transgene expression
could be detected in sections obtained from animals given the 0.05-ND50 preparation (I to L), and the level was significantly lower than that for mice given the
virus alone at all time points (A to D).
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the virus-antibody combinations all fell within the accepted nor-
mal range for C57BL/6 mice throughout the study (40). A similar
trend was observed for ALT; however, transaminase levels of ani-
mals given the 5- and 0.05-ND50 preparations were notably higher
than baseline levels 7 days after treatment (55.2 4.6 and 49.8
3.2 U/liter, respectively, versus 26.6 1.9 U/liter PBS; P 0.05)
(Fig. 5C).
Refinement and selectionof additional virus-antibody ratios
for further investigation in naïve mice and those with preexist-
ing immunity. Critical evaluation of data identified the 0.05-
ND50 antibody concentration as the one that most closely fit our
criteria for a suitable vaccine candidate, since it elicited the stron-
gest T and B cell responses to the transgene and minimized virus-
associated toxicity. Although the 500- and 5-ND50 preparations
prevented notable transgene expression in any of the organs
screened by histochemical staining and ELISA (data not shown),
moderate levels of transgene expression in organs of animals given
the 0.05-ND50 preparation suggested that this may not be the true
optimum and that another antibody-virus ratio may further im-
prove the transgene-specific immune response. In this regard, two
additional virus-antibody concentrations were selected (0.005
and 0.0005 ND50) for toxicological and immunological compari-
son with virus alone in naïve mice and those with preexisting
immunity to adenovirus.
Effect of reducing the amount of anti-adenovirus antibody
on the immune response against the transgene. The transduc-
tion efficiency of preparations made with the revised antibody
concentrations was similar to free virus in vitro and in vivo. The
infectious titer of the 0.005-ND50 preparationwas reduced by only
a factor of 2, while that of the 0.0005-ND50 preparation was not
significantly different from that of virus alone (Table 1). Although
Western blotting revealed that the 0.005-ND50 preparation bound
hexon (lane 4, Fig. 2B), protein binding could not be detectedwith
the 0.0005-ND50 dilution (lane 5, Fig. 2B). Visual inspection of
sections of spleen and liver histochemically stained for beta-
galactosidase also revealed that each of these preparations trans-
duced these organs in amanner similar to that of virus alone (data
not shown).
Peptide-specific activation of CD8 T cells, evaluated by the
production of IFN-, was detected in splenocytes of mice given
the 0.005- and 0.0005-ND50 preparations at frequencies of 4.2 1
and 2.7  1.1%, respectively (Fig. 6A). These values were not
statistically different from those of mice given virus alone (3.1
1.0%, P 0.06). The frequency of IFN--secreting CD8 T cells
FIG 4 VACs at a concentration of 0.05 ND50 can elicit strong T-cell mediated and humoral immune responses against an encoded transgene. (A) CTL responses
elicited by VACs. Splenocytes harvested 10 days after treatment were restimulated in vitro for 5 days and tested for specific lysis onMC57 target cells infected with
adenovirus expressing beta-galactosidase in a 6-h 51Cr release assay. Percent specific lysis is expressed as a function of different effector-to-target ratios (6:1,
12.5:1, 25:1, 50:1, and 100:1). (B) Anti-beta-galactosidase neutralizing antibody profile after a single dose of VACs in C57BL/6mice. Serumwas analyzed 28 days
after treatment for the presence of antibody to beta-galactosidase. Fifty percent endpoint titers were calculated according to themethod of Reed andMuench. (C)
Anti-adenovirus neutralizing antibody levels. The presence of neutralizing antibody against the adenoviral vector was determined by assessing the ability
of collected sera to block infection of HeLa cells by virus expressing beta-galactosidase. The 50% endpoint titer is plotted according to treatment. (D)
Memory response. Splenocytes were isolated 42 days after treatment, stained with CFSE, and stimulated with beta-galactosidase-specific peptide for 5
days. Cells positive for CD8, CD44hi, and CD62Llo were evaluated for CFSE staining by flow cytometry. Data represent the degree of effector CD8 T cell
expansion after stimulation. Data illustrated in each panel reflect the means and standard deviations of results for five animals per group. Statistical
significance was determined between individual treatment groups and vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post hoc
test. , P  0.05; , P  0.01.
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in mice given the 0.05-ND50 preparation was twice this value
(6.2 1.1%). Therewas no significant difference in the amount of
anti-beta-galactosidase antibody in serum from animals given ei-
ther the 0.005-ND50 preparation (383  150) or virus alone
(226 116 50% endpoint titer; P 0.07) (Fig. 6B). A significant
increase in anti-transgene antibodies was noted for animals given
the 0.0005-ND50 preparation (2,698  337 50% endpoint titer).
Antibody titers of the 0.05-ND50 group were slightly lower than
those of the group given virus alone (134.5 22.2). Samples from
animals given the 0.05-ND50 preparation also contained anti-
adenovirus antibodies at a concentration not significantly differ-
ent from mice given virus alone (108.5  30.5 and 175.1  47.5
50% endpoint titer, respectively; P 0.06) (Fig. 6C). In contrast,
anti-adenovirus antibody levelswere significantly elevated in sam-
ples from the 0.005-ND50 (383 98 50% endpoint titer;P 0.05)
and the 0.0005-ND50 (2,691 624 50% endpoint titer; P 0.01)
groups. Significant proliferation of beta-galactosidase-specific ef-
fector memory CD8 T cells was detected in mice given the 0.05-
ND50 preparation (13.2% 1%) with respect to mice given virus
alone (4.9 0.8%; P 0.01) (Fig. 6D). Thememory response was
significantly reduced to 1.9 0.5% in mice given the 0.005-ND50
preparation (P  0.05), while that of animals given virus with
antibody at a concentration of 0.0005 ND50 was not significantly
different from that of mice given virus alone (4.2  1.2%; P 
0.06).
Effect of preexisting immunity to adenovirus on the in vivo
performance of VACs. PEI significantly compromised the pro-
duction of beta-galactosidase-specific IFN--secreting CD8 T
cells in mice given virus alone (5.0  0.9% [naïve] versus 1.23%
[PEI];P 0.01) (Fig. 7A). Although PEI did reduce the number of
IFN- CD8 T cells in mice given the 0.05-ND50 preparation
from 6.2 0.6 to 4.6 0.2%, the latter value was still 4 times that
for mice given virus alone. Prior exposure to adenovirus did not
affect the transgene-specific T cell response in mice given the
0.0005-ND50 preparation (2.70  0.4% [naïve] versus 1.96% 
0.5% [PEI]) and significantly improved the response ofmice given
the 0.005-ND50 formulation (4.20 0.5% [naïve] versus 6.70%
0.1% [PEI]; P 0.01).
PEI significantly reduced the amount of circulating anti-beta-
galactosidase antibodies in mice given virus alone by a factor of
150 (25,542  748 [naïve] versus 163.3  79.7 [PEI] 50% end-
point titer, Fig. 7B). A similar trend was noted for the 0.005-ND50
preparation (16,306  202.86 [naïve] versus 121.1  59.9 [PEI]
50% endpoint titer). PEI also reduced the number of circulating
anti-beta-galactosidase antibodies in mice given the 0.05-ND50
preparation but to a lesser degree (17,382.3  445 [naïve] to
955  53.5 [PEI] 50% endpoint titer). Antibody titers in mice
given the 0.0005-ND50 preparation increased under these condi-
tions from 60.3  10.9 (naïve) to 600.5  44.7 (PEI) 50% end-
point titer. This specific preparation also induced production of
FIG 5 VACs significantly reduce virus-induced toxicity. (A) Serum cytokine levels. IL-6 and IL-12 (p70) were assessed 6 h after systemic administration of a
single dose of either virus alone (1 1011 virus particles), the same dose of virus mixed with different amounts of anti-adenovirus antibody, or saline (PBS). (B)
Platelets. Fourteen days before treatment, baseline platelet counts were determined (t 0). A notable drop in platelet count was observed only in animals given
virus alone. (C) Kinetic profile of serum alanine aminotransferase (ALT). Normal levels for C57BL/6 mice fall within the range of 24 to 140 U/liter (40). (D)
Kinetic profile of serum aspartate aminotransferase (AST). Normal levels for C57BL/6 mice fall within the range of 72 to 288 U/liter (40). In each panel, data
reflect average values  the standard error of the mean for 5 mice from each treatment group. Statistical significance was determined between individual
treatment groups and vehicle controls by one-way analysis of variance with a Bonferroni/Dunn post hoc test. , P 0.05; , P 0.01.
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anti-adenovirus antibodies in naïve mice to a level that was ap-
proximately 9 times that of mice given virus alone (Fig. 7C). Pre-
existing immunity did not significantly alter the amount of anti-
bodies produced against the virus in this group (2,691  624
[naïve], 1,415  660 [PEI] 50% endpoint titer, P  0.056). PEI
boosted the amount of anti-adenovirus antibodies produced by
mice given the 0.005-ND50 and 0.05-ND50 preparations by factors
of 9 and 4, respectively. The highest increase in antibody produc-
tion was noted, however, in mice given virus alone (308  47.5
[naïve], 3,704 613 [PEI] 50% endpoint titer).
The memory response of mice given virus alone was not com-
promised by PEI, since 4.9 0.8% effectormemory cells from this
group responded to the transgene-specific peptide and 4.4 1.7%
from thosewith PEI responded in the samemanner (P 0.72; Fig.
7D). The memory response was significantly reduced in mice
given the 0.0005-ND50 preparation (4.17  1.2% [naïve] versus
1.2 0.1 [PEI]; P 0.01). A less significant reduction was noted
with the 0.05-ND50 preparation (13.2 1.0% [naïve] versus 7.7
2.4 [PEI]; P  0.05). In contrast, PEI increased the memory re-
sponse elicited by the 0.005-ND50 preparation 3-fold from 1.9
0.5% proliferating effector cells (naïve) to 6.0 1.0% (PEI).
Cytokine secretionpatternsandclinical chemistryprofilesof
optimized virus-antibody complexes. PEI increased serum IL-6
and IL-12 in mice given the 0.005-ND50 preparation 3.5 and 5.4
times baseline, respectively (P 0.01; Fig. 8A and 8B). In contrast,
PEI did not significantly alter cytokine levels of mice treated with
virus alone and the 0.0005-ND50 preparation (P 0.05). Samples
frommice given the 0.05-ND50 formulation contained the small-
est amount of both IL-6 (17.6  4.7 [naïve] versus 21.8  6.5
[PEI] pg/ml) and IL-12 (27.6 9.4 [naïve] versus 28.8 6.3 [PEI]
pg/ml). Evaluation of serum transaminases 7 days after adminis-
tration of virus alone revealed that PEI significantly reduced both
ALT (709.5 [naïve] versus 51.4 U/liter [PEI]) and AST (1,192.5
[naïve] versus 232.2 U/liter [PEI]; P  0.01; Fig. 8C and 8D).
Serum transaminases fell within normal ranges for mice in the
other treatment groups throughout the course of the study. Al-
though a significant drop in platelets was noted for naïve mice
given either virus alone or the 0.0005-ND50 preparation (Fig. 8E),
this effect was absent in mice with PEI given the 0.0005-ND50
preparation (Fig. 8F). Platelets dropped from baseline (1,322 
103/l) to 582.5 103/l in mice with PEI given the 0.005-ND50
preparation (P  0.01; Fig. 8F). Thrombocytopenia was not ob-
served in naïve mice or those with PEI given the 0.05-ND50 prep-
aration.
DISCUSSION
The experiments described in this paper were primarily designed
to determine if virus-antibody complexes can be optimized to
effectively influence the strength and type of immune response
elicited by a recombinant adenovirus. While this certainly is not
FIG 6 Anti-adenovirus antibody at a concentration of 0.05 ND50 facilitates strong effector memory responses against an encoded transgene in naive mice. (A)
Frequency of IFN--secreting CD8 T cells. Naïve mice were given either virus alone (1 1011 virus particles), the same amount of virus mixed with different
concentrations of anti-adenovirus antibody, or saline (PBS, negative control) systemically. Ten days later, 1 106 splenocytes from each animal were incubated
with a beta-galactosidase-specific peptide and responsive cells analyzed by flow cytometry. (B) Anti-beta-galactosidase neutralizing antibody profile. Serumwas
analyzed 28 days after treatment by ELISA. Fifty percent endpoint titers were calculated according to the method of Reed and Muench. (C) Anti-adenovirus
neutralizing antibody. NAB titers were determined by assessing the ability of collected sera to block infection of HeLa cells by adenovirus expressing beta-
galactosidase. The 50% endpoint titer is plotted according to treatment. (D) Memory response. Splenocytes were isolated 42 days after treatment, stained with
CFSE, and stimulated with beta-galactosidase-specific peptide. CD8 cells also positive for CD44hi and CD62Llo were evaluated for CFSE staining by flow
cytometry. Data illustrated in each panel reflects the means and standard errors of the means for five animals per group. Statistical significance was determined
between individual treatment groups by one-way analysis of variance with a Bonferroni/Dunn post hoc test. , P 0.05; , P 0.01.
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the first report describing a strategy for targeting Fc receptors on
antigen-presenting cells to improve the potency of vaccine candi-
dates (14, 18, 39), it is the first, to our knowledge, that makes a
concerted effort to identify specific virus:antibody ratios that
strengthen the immunogenicity of a recombinant adenovirus.
Data obtained from our initial pilot study revealed that the im-
mune response against an encoded transgene could be enhanced
by virus-antibody complexes and the degree of enhancement is
ratio dependent. The absence of transgene expression in tissues
isolated from mice given the 500- and 5-ND50 preparations and
data from infectious titer assays illustrate that, at these concentra-
tions, the antibody stock could effectively neutralize the virus in
vitro and in vivo. Although these preparations elicited strong,
short-term T cell responses in naïve mice, a measurable humoral
response against the transgene was not established (Fig. 4). In
contrast, the same amount of virus mixed with antibody at a con-
centration of 0.05 ND50 could induce both cellular and humoral
responses, similar to the virus alone with moderate amounts of
transgene expression noted in target tissues (Fig. 3). This suggests
that (i) a robust immune response to an encoded transgene re-
quires some balance between direct uptake and processing of virus
particles by antigen-presenting cells and effective transduction of
target cells and tissues in the whole animal and (ii) that these
complexes could be used to incite tailored immune responses for
particular disease targets.
Physical characterization of virus-antibody complexes by
dynamic light scattering revealed that over 90% of the particles
present in the 500-ND50 preparation had average hydrody-
namic radii of 3,862 nm and 76% of the 5-ND50 preparation
contained particles of similar size. Characterization of anti-
body isotypes in the stock serum used to generate the com-
plexes suggests that anti-adenovirus IgM antibodies facilitated
aggregation of virus particles in these preparations (Fig. 2A). In
contrast, the 0.05-ND50 preparation consisted primarily of
particles with radii similar to that of a single adenovirus parti-
cle (83.4  12.9 nm). Large particles (1 m) are toxic to
antigen-presenting cells and can induce spontaneous apoptosis
or necrosis accompanied by the release of proinflammatory
cytokines (33, 48). This also has been described for adenovirus
infection with the rapid destruction of Kupffer cells noted im-
mediately after systemic administration of large amounts of
virus (26, 30, 55). Thus, we believe the initial strong T cell-
mediated immune response generated by these preparations
was partly in response to spontaneous destruction of antigen-
presenting cells. Opsonization of virus particles through the
complement system was most likely responsible for the low
FIG 7 Preexisting immunity to adenovirus serotype 5 does not significantly compromise the immune response elicited by someVACs. Preexisting immunitywas
established by intramuscular injection of 1  1011 particles of AdEGFP 28 days prior to administration of VACs. At that time, mice had a circulating
anti-adenovirus NAB titer of a 184.2 32.4 reciprocal dilution. Animals given saline served as negative controls (PBS). (A) Frequency of IFN--secreting CD8
T cells. Ten days after treatment, 1 106 splenocytes from each animal were harvested and incubated with a beta-galactosidase-specific peptide. Responsive cells
were quantitated by flow cytometry. (B) Anti-beta-galactosidase antibody profile after administration of VACs. Serumwas analyzed 28 days after treatment. Fifty
percent endpoint titers are plotted according to treatment and were calculated according to the method of Reed andMuench. (C) Anti-adenovirus neutralizing
antibody. Neutralizing antibody titers were determined by assessing the ability of sera to block infection of HeLa cells by unmodified virus expressing beta-
galactosidase. The 50% endpoint titer is plotted according to treatment. (D)Memory response. Cells positive for CD8, CD44hi, andCD62Llo were evaluated for
CFSE staining by flow cytometry. Data represent the degree of effector CD8T cell expansion after stimulation for each treatment group. Data illustrated in each
panel reflect themeans and standard errors of themeans for five animals/group. Statistical significance was determined between individual treatment groups and
vehicle controls or between naïve animals and those with preexisting immunity to adenovirus by one-way analysis of variance with a Bonferroni/Dunn post hoc
test. , P 0.05; , P 0.01. PEI, preexisting immunity to adenovirus.
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levels of anti-adenovirus antibodies and effector memory T
cells found in mice given these preparations.
Data generated with preparations in the 0.05 to 0.0005-ND50
range also suggest that the amount of neutralizing antibody pres-
ent in a virus-antibody complex can influence the type and quality
of immune response elicited against a transgene cassette. Admin-
istration of virus mixed with the antibody at a concentration of
0.05 ND50 favored the T cell-mediated response (Fig. 4 and 6).
This was most likely achieved by reinforcement of the early T cell
response initiated by free virions through preferential activation
of macrophages and dendritic cells by virus-antibody complexes,
resulting in a significant increase in transgene-specific memory
effector cells (31, 36, 60). Although the 0.005- and 0.0005-ND50
combinations did not improve the transgene-specific cellular or
humoral immune responses with respect to the virus alone in
naïve animals (Fig. 6), they did strengthen certain arms of the
immune response inmice with preexisting immunity (Fig. 7). For
example, cytokine secretion was significantly increased by the
0.005-ND50 formulation in mice with preexisting immunity (Fig.
8). This effect, in concert with this specific virus-antibody ratio,
fostered strong cellular responses in the form of increased num-
bers of transgene-specific IFN--secreting CD8T cells and effec-
FIG 8 VACs at a 0.05-ND50 ratio significantly reduce the cytokine response and virus-induced thromobcytopenia inmice with PEI. (A) IL-6 secretion. IL-6 was
assessed in serum collected 6 h after systemic administration of either virus alone (AdlacZ), virus mixed with different concentrations of anti-adenovirus
antibody, or saline (PBS). (B) IL-12 secretion. IL-12 (p70) was also measured 6 h after treatment from a minimum of five mice per group. (C) Serum alanine
aminotransferase (ALT). ALTwasmeasured at the timewhen significant increases are commonly noted inmice given virus alone, 7 days after treatment. Normal
levels for C57BL/6 mice are 24 to 140 U/liter (40). (D) Serum aspartate aminotransferase (AST). AST was also measured at the time when significant increases
are commonly noted inmice given virus alone, the 7-day time point. AST levels normally fall within the 72- to 288-U/liter range (40). (E)Kinetic profile of platelet
counts for naïve mice. Fourteen days before treatment, baseline platelet counts were determined (t  0). Notable thrombocytopenia was detected in animals
given virus alone and the 0.0005-ND50 preparation. (F) Kinetic profile of platelet counts for mice with PEI. Platelet counts were significantly reduced in mice 3
days after virus to establish PEI was given, with levels returning to baseline prior to administration of VACs 28 days later (data not shown). In each panel,
statistical significance was determined either between individual treatment groups and vehicle controls or between naïve animals and those with preexisting
immunity to adenovirus by one-way analysis of variance with a Bonferroni/Dunn post hoc test. , P 0.05; , P 0.01.
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tor memory cells higher than those elicited by virus alone under
the same conditions (Fig. 7). Although cytokine secretion was not
enhanced by preexisting immunity in animals given the 0.0005-
ND50 preparation, this combination was sufficient to improve the
humoral response against beta-galactosidase without significantly
increasing the response to the virus capsid (Fig. 7). This may be
due to the ability of this combination to target virus to different
cellular compartments and sufficiently alter antigen trafficking
and processing in amanner that facilitates this armof the immune
response (25, 59). In order to define the limits to which one armof
the immune response can be influenced by virus-antibody com-
plexes, additional studies within narrower antibody concentra-
tion ranges are under way in our laboratories.
A critical issue to the development of adenovirus-based vac-
cines is the reliability of in vitro neutralization assays to predict
the effect of anti-virus antibodies on the in vivo performance of
the vector (9, 37, 38). In this context, it is important to realize
that the extent to which serum can effectively neutralize virus
infection is determined by several factors. The presence (or ab-
sence) of particular antibody isotypes and their respective affinity
for antigenic epitopes on the virus can significantly effect the
neutralization properties of serum. The number and identity of
antigenic epitopes against which antibodies are generated, the
concentration of nonimmune components that promote virus
infection (clotting factors), and the presence/absence of virus-
specific and Fc receptors on the cell line used in testing serum also
influence the results of neutralizing assays and the ability to pre-
dict the performance of adenoviruses in vivo (35, 38). Character-
ization of our stock serum revealed that multivalent IgM antibod-
ies as well as IgG antibodies capable of binding all major virus
capsid proteins were present in preparations in which large aggre-
gates of virus particles were detected (Fig. 2). This provides a valid
explanation for the immunological responses elicited by com-
plexes formedwith high concentrations of antibody stock and also
demonstrates the role that antibody isotype and specificity plays in
the immune response against the adenovirus and its encoded an-
tigen. IgG2b antibodies were the most abundant isotype in each
dilution used in the studies outlined in this paper (Fig. 2A). Of all
the IgG subclasses, this isotype has the lowest affinity for Fc recep-
tors on phagocytic cells and only binds to one Fc receptor, FcR
II (45). Engagement of the two isoforms of this receptor, FcR IIA
and FcR IIB, can have opposing effects, with FcR IIA eliciting a
stimulatory signal and FcR IIB inhibiting immune activation.
Taken together, these two effects may be responsible for the vari-
ability in the immune responses elicited in vivo by preparations
containing the lowest antibody concentrations, which could not
be predicted using standard in vitro neutralization assays. Most
recently, Perreau et al., using an antibody stock preparationwith a
composition similar to ours, demonstrated that FcR IIA recep-
tors do play a key role in antibody-mediated immune responses
against adenoviral vectors (36).
Certain antibody isotypes have also been shown to mediate
platelet clearance in a differential manner, which could explain
why the toxicity profiles of the virus-antibody complexes was sig-
nificantly lower than that of virus alone (29) (Fig. 8). In contrast to
most adenovirus-based vaccines to date, the vector used to gener-
ate the data described in this paper contained a nonsecreted trans-
gene (24). Additional studies with an immunologically relevant
transgene cassette to assess the immune response in the context of
protective immunity after antigenic challenge will further estab-
lish the clinical utility of virus-antibody complexes for vaccination
purposes. The fact that most of the virus-antibody preparations
tested strengthened the humoral immune response to adenovirus
in mice with established preexisting immunity suggests that sys-
temic administration of this type preparation is not yet a viable
therapeutic option in this particular patient population. Addi-
tional evaluation of this approach in naïve animals and models of
preexisting immunity with well-characterized lots of monoclonal
antibodies will be the focus of future studies.
To our knowledge this is the first report describing the im-
munological profile of a defined series of antibody:adenovirus
combinations in both naïve mice and those with preexisting
immunity. Although correlations between anti-adenovirus cel-
lular immune responses and neutralizing antibody titers in the
clinic have been described (4, 10), this concept has not been ex-
tensively investigated in the context of the transgene-specific re-
sponse in preclinical animal models as described in these studies.
Subtle changes in the type of immune response elicited against the
transgene by complexes formed with very low antibody concen-
trations suggest that information generated from studies such as
this would be useful in the assessment of clinical candidates for
which a particular immune response is desired. Additional work
in larger animal models with paired evaluation of clinical data is
also warranted, not only to determine if this would be of benefit in
the optimization of vaccination protocols but also to determine
when and if these complexes may establish conditions that are
inappropriate for certain antigens and disease states.
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